Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00468910 · ClinicalTrials.gov registry record · Phase 2

Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer

A Phase 2 study, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
79
Enrollment target

NCT00468910: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).

NCT00468910 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 79 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00468910, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
79 participants
Enrollment target

Study Summary

This randomized phase II trial is studying how well aspirin works in preventing colorectal cancer in patients at increased risk of colorectal cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of aspirin may prevent colorectal cancer.

Primary Outcome

Spectral marker assessment was performed via LEBS analysis (low-coherence enhanced backscattering spectroscopy) on the uninvolved mucosal biopsies of subjects taken at baseline and after 3 months of treatment with either aspirin or placebo. SPEC characterizes the size distribution of macromolecular complexes and other intracellular structures, with a decrease of the spectral slope implying a shift of the size distribution of intracellular structures toward smaller sizes. Spectral markers SPEC a

Interventions

  • DRUG placebo
  • OTHER laboratory biomarker analysis
  • DRUG acetylsalicylic acid

Trial Details

FieldValue
Enrollment Target 79 participants
Start Date 2007-03
Est. Completion 2011-08
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00468910 record still lists

NCT00468910 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 79 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower).

The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.

NCT00468910 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00468910 about?

NCT00468910 is a clinical study titled "Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer". This randomized phase II trial is studying how well aspirin works in preventing colorectal cancer in patients at increased risk of colorectal cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of aspirin may prevent colorectal cancer.

What is the current status of trial NCT00468910?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2007-03. Estimated completion is 2011-08.

What interventions are being tested in trial NCT00468910?

The interventions under investigation include: placebo (DRUG), laboratory biomarker analysis (OTHER), acetylsalicylic acid (DRUG).

Who is sponsoring clinical trial NCT00468910?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00468910's enrollment target sits among peer trials

79 884th of 2000 higher than 1,117 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05798897 · 79 participants · Phase 1

    Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

  • NCT06042439 · 79 participants · NA

    AM vs PM Exercise Training

  • NCT06223555 · 79 participants · NA

    Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00468910, the US trial registry maintained by the National Library of Medicine. NCT00468910 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.